EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Impact of the serrated pathway on the simulated comparative effectiveness of colorectal cancer screening tests

Reinier G S Meester iD, Uri Ladabaum

JNCI Cancer Spectrum · 2024

DOI: 10.1093/jncics/pkae077 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Reinier G S Meester und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonoscopy, Cost-Benefit Analysis, Quality-Adjusted Life Years. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancers (CRCs) arise from adenomas, which can produce fecal occult blood and can be detected endoscopically, or sessile serrated lesions (SSLs), which rarely bleed and may be more challenging to detect. Models informing CRC screening policy should reflect both pathways, accounting for uncertainty.

Methods

Novel decision-analytic model of the adenoma and serrated pathways for CRC (ANSER) to compare current and emerging screening strategies, accounting for differential test sensitivities for adenomas and SSLs, and uncertainty. Strategies included colonoscopy every 10 years, stool-DNA/FIT (sDNA-FIT) every 1-3 years, or fecal immunochemical testing (FIT) every year from age 45 to 75 years. Outcomes included CRC cases and deaths, cost-effectiveness (cost/quality-adjusted life-year [QALY] gained), and burden–benefit (colonoscopies/life-year gained), with 95% uncertainty intervals (UIs).

Results

ANSER predicted 62.5 (95% UI = 58.8-66.3) lifetime CRC cases and 24.1 (95% UI = 22.5-25.7) CRC deaths/1000 45-year-olds without screening, and 78%-87% CRC mortality reductions with screening. The tests’ outcome distributions overlapped for QALYs gained but separated for required colonoscopies and costs. All strategies cost less than $100 000/QALY gained vs no screening. Colonoscopy was the most effective and cost-effective, costing $9300/life-year gained (95% UI = $500-$21 900) vs FIT. sDNA-FIT cost more than $500 000/QALY gained vs FIT. As more CRCs arose from SSLs, colonoscopy remained preferred based on clinical benefit and cost-effectiveness, but cost-effectiveness improved for a next-generation sDNA-FIT.

Conclusion

When the serrated pathway is considered, modeling suggests that colonoscopy is cost-effective vs FIT. In contrast, modeling suggests that sDNA-FIT is not cost-effective vs FIT despite its greater sensitivity for SSLs, even if a substantial minority of CRCs arise from SSLs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonoscopyCost-Benefit AnalysisQuality-Adjusted Life YearsOccult BloodAdenomaEarly Detection of CancerFecesHumansMiddle AgedAgedFemaleMaleDecision Support TechniquesUncertaintySensitivity and SpecificityComparative Effectiveness ResearchDNA, Neoplasm

Substanzen

DNA, Neoplasm

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
  • Health Economics and Outcomes Research, Freenome Holdings, Inc, South San Francisco, CA, USA.

ORCID-Profile: Reinier G S Meester

Förderung

  • Dutch Research Council

Zitieren

APA

Meester, R. G. S., & Ladabaum, U. (2024). Impact of the serrated pathway on the simulated comparative effectiveness of colorectal cancer screening tests. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae077

Vancouver

Meester RGS, Ladabaum U. Impact of the serrated pathway on the simulated comparative effectiveness of colorectal cancer screening tests. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae077

BibTeX
@article{Meester2024,
  author = {Meester, Reinier G S and Ladabaum, Uri},
  title = {Impact of the serrated pathway on the simulated comparative effectiveness of colorectal cancer screening tests},
  journal = {JNCI Cancer Spectrum},
  year = {2024},
  doi = {10.1093/jncics/pkae077}
}
Kostenlos starten →